National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Dapagliflozin (Forxiga®)

Dapagliflozin (Forxiga®) is indicated in adults aged 18 years and older with Type 2 Diabetes Mellitus to improve glycaemic control as:
When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.
Add-on combination therapy
In combination with other glucose lowering drugs including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.

Rapid Review

Commenced Completed Outcome
10th October 2012 22nd October 2012 Full pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
01/08/2013  31/12/2013 Reimbursement not recommended at this time.


December 2015

The HSE has approved reimbursement following confidential price negotiations.